NCT00338026已完成1 期
A Phase I, Dose Finding, Pharmacokinetic, and Safety Study of Continuous IV Infusion of ECO-4601 in Patients With Advanced Cancer Including an Extension Portion to Obtain Safety Data at the Highest Tolerable Dose
Thallion Pharmaceuticals2 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2006年2月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 26
- 试验地点
- 2
- 主要终点
- Safety/tolerability of ECO-4601
研究概览
简要总结
The purpose of this study was to determine the maximum tolerated dose (MTD) and the recommended dose for future studies of ECO-4601 administered as a continuous IV infusion for 14 days with 7 days recovery (21 day cycle) in patients with histologically confirmed solid tumors (high grade glioma, colorectal, lung, breast, ovarian, pancreatic and prostate). This study was also designed to determine the clinical pharmacokinetic profile, safety of multiple cycles of administration, and document the antitumor activity of ECO-4601.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Informed about the study and consent to participate in the study
- •Clinically or radiologically documented advanced solid malignancy for which no standard therapy is available, or which has failed standard therapy
- •Patients with the following solid tumors: high grade glioma, colorectal, prostate, pancreatic, lung, ovarian and breast carcinoma
- •Age ≥ 18 years of age
- •Laboratory hematology and biochemistry protocol test result abnormalities ≤ Grade 1, graded using NCI CTCAE version 3.0
- •Patients with no chemotherapy during the 4 weeks preceding patients' first dose of ECO-4601 (day 1, cycle 1)
- •No other anticancer treatment during the study
- •Patients can be receiving stable or decreasing dose of steroids within 2 weeks prior to patient's signature of the informed consent
- •Patients must be accessible for treatment and follow-up. Patients registered on this trial must be treated and followed at the participating centre
- •Previous Therapy
- •Hormonal therapy: Patients may have had prior hormonal therapy provided it is discontinued upon ICF signature
- •Radiation: Patients may have had prior radiation therapy. Patients must have recovered from the acute toxic effects of radiotherapy
- •Previous surgery: Previous surgery is permitted provided that at least 2 weeks have elapsed between major surgery (non-biopsy) and ICF signature
排除标准
- •Patients with brain metastases
- •Unlikely to comply with protocol or difficulty to understand the purpose of the study
- •Life expectancy < 12 weeks
- •Clinically significant co-morbid disease, e.g. renal failure, ischemic vascular disease, uncontrolled seizure, dementia
- •Any patient with a potentially curable malignancy who has not yet received appropriate standard therapies
- •Anti seizure drugs known inducers of cytochrome P450
- •Documented HIV, active hepatitis B or C infections
- •Patients with active or uncontrolled infections or with serious illnesses or medical conditions, which would not permit the patient to be managed according to protocol
- •Pregnant or lactating women; both men and women enrolled on study should be using adequate birth control measures throughout the course of the study. Women of childbearing potential must have a negative serum or urine pregnancy test documented within 14 days prior to registration and at study start
- •Inability or refusal to practice contraception during therapy of ECO-4601, unless patient is surgically sterile or woman is postmenopausal for at least 2 years
- •Patients who have been treated with any investigational drug within 4 weeks of patient's signature of informed consent form, or who are receiving concurrent treatment with other experimental drugs or anti cancer therapy
- •Patients in whom a proper central line cannot be established
- •Concomitant therapy with therapeutic coumadin; patients can be transferred to low molecular weight heparin
- •Patients on low molecular weight heparin for < 2 weeks prior to ICF signature
- •Polysorbate 80 being a major constituent of ECO-4601 and known to cause hypotension, patients with uncontrolled hypotension will be excluded
- •Known hypersensitivity to farnesylated dibenzodiazepinone or any of the formulation components
- •Concomitant Therapy Permitted:
- •Patients may receive ongoing supportive and palliative care (eg: pain control) as clinically indicated throughout the study.
- •Patients can be treated with corticosteroids if medically needed
- •Usage of low molecular weight heparin is allowed
- •Anti seizure products are permitted provided they are not inducers of cytochrome P
- •Concomitant Therapy Not Permitted:
- •Other anticancer treatment
- •Other investigational therapy
- •Concomitant therapy with coumadin
- •Cytochrome enzyme inducing anti epileptics
- •G-CSF, GM-CSF and other growth factors may not be used as a substitute for a scheduled dose reduction; however they may be used in the management of acute toxicity such as febrile neutropenia when clinically indicated at the discretion of the investigator. Use of erythropoietin is allowed if treatment has been initiated for ≥ 2 months. Use of growth factors must be documented on case report forms.
- •Hormonal therapy
研究组 & 干预措施
ECO-4601
Experimental
干预措施: ECO-4601 (Drug)
结局指标
主要结局
Safety/tolerability of ECO-4601
Determination of MTD of ECO-4601
Determination of recommended dose for future studies of ECO-4601
次要结局
- Pharmacokinetics of ECO-4601
- Safety of multiple cycles of administration of ECO-4601
- Documentation of ECO-4601 antitumor activity as per RECIST criteria
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573NeoplasmsNCT02405065Hanmi Pharmaceutical Company Limited72
已完成
1 期
Study of RP-3500, Camonsertib, in Advanced Solid TumorsAdvanced Solid TumorNCT04497116Repare Therapeutics276
已完成
1 期
A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic CarcinomaNeoplasms, LiverNCT00629759Jennerex Biotherapeutics14
已完成
1 期
First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C MutationNeoplasmsAdvanced Solid TumorsColorectal CancerNon-small Cell Lung CancerNCT04006301Janssen Research & Development, LLC10
已完成
1 期
Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)Gastrointestinal Stromal TumorsSoft Tissue SarcomasNCT00276302Infinity Pharmaceuticals, Inc.63